Literature DB >> 7831453

A comparison of delusional and nondelusional body dysmorphic disorder in 100 cases.

K A Phillips1, S L McElroy, P E Keck, J I Hudson, H G Pope.   

Abstract

A controversial issue that was debated for DSM-IV is whether body dysmorphic disorder (BDD)--a preoccupation with an imagined defect in appearance--can be psychotic. BDD is classified separately from its delusional counterpart (delusional disorder, somatic type) in DSM-IV, but does it have a psychotic variant that overlaps with, and may even be the same diagnostic entity as, its delusional disorder variant? One hundred consecutive patients with DSM-III-R-defined BDD or its delusional variant were assessed with a semistructured interview, the Structured Clinical Inverview for DSM-III-R, and a modified version of the Yale-Brown Obsessive Compulsive Scale (Y-BOCS). The 48 patients with nondelusional BDD were compared with the 52 patients with delusional BDD (i.e., delusional disorder, somatic type). The two groups did not differ significantly in terms of most variables examined, including demographics, phenomenology, course, associated features, comorbidity, and treatment response. Thus, BDD may have a psychotic subtype that significantly overlaps with, and may even be the same disorder as, its delusional disorder variant. However, delusional subjects had higher total scores on the modified Y-BOCS, suggesting that the delusional variant of BDD may be a more severe form of the disorder. Although preliminary, these findings have implications for BDD's treatment and classification, suggesting that inclusion of a delusional (psychotic) subtype of BDD should be considered for future editions of DSM.

Entities:  

Mesh:

Year:  1994        PMID: 7831453

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  47 in total

Review 1.  The obsessive-compulsive spectrums.

Authors:  Katharine A Phillips
Journal:  Psychiatr Clin North Am       Date:  2002-12

Review 2.  Olfactory reference syndrome: issues for DSM-V.

Authors:  Jamie D Feusner; Katharine A Phillips; Dan J Stein
Journal:  Depress Anxiety       Date:  2010-06       Impact factor: 6.505

Review 3.  Body dysmorphic disorder: some key issues for DSM-V.

Authors:  Katharine A Phillips; Sabine Wilhelm; Lorrin M Koran; Elizabeth R Didie; Brian A Fallon; Jamie Feusner; Dan J Stein
Journal:  Depress Anxiety       Date:  2010-06       Impact factor: 6.505

4.  Modular cognitive-behavioral therapy for body dysmorphic disorder: a randomized controlled trial.

Authors:  Sabine Wilhelm; Katharine A Phillips; Elizabeth Didie; Ulrike Buhlmann; Jennifer L Greenberg; Jeanne M Fama; Aparna Keshaviah; Gail Steketee
Journal:  Behav Ther       Date:  2013-12-29

5.  Delusional versus nondelusional body dysmorphic disorder: clinical features and course of illness.

Authors:  K A Phillips; W Menard; M E Pagano; C Fay; R L Stout
Journal:  J Psychiatr Res       Date:  2005-10-17       Impact factor: 4.791

6.  A retrospective follow-up study of body dysmorphic disorder.

Authors:  Katharine A Phillips; Jon E Grant; Jason M Siniscalchi; Robert Stout; Lawrence H Price
Journal:  Compr Psychiatry       Date:  2005 Sep-Oct       Impact factor: 3.735

7.  Demographic characteristics, phenomenology, comorbidity, and family history in 200 individuals with body dysmorphic disorder.

Authors:  Katharine A Phillips; William Menard; Christina Fay; Risa Weisberg
Journal:  Psychosomatics       Date:  2005 Jul-Aug       Impact factor: 2.386

8.  Predictors of remission from body dysmorphic disorder: a prospective study.

Authors:  Katharine A Phillips; Maria E Pagano; William Menard; Christina Fay; Robert L Stout
Journal:  J Nerv Ment Dis       Date:  2005-08       Impact factor: 2.254

9.  A 12-month follow-up study of the course of body dysmorphic disorder.

Authors:  Katharine A Phillips; Maria E Pagano; William Menard; Robert L Stout
Journal:  Am J Psychiatry       Date:  2006-05       Impact factor: 18.112

10.  Body dysmorphic disorder: recognizing and treating imagined ugliness.

Authors:  Katharine A Phillips
Journal:  World Psychiatry       Date:  2004-02       Impact factor: 49.548

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.